Title: Racemic mixtures and single stereoisomers: Industrial concerns and issues in drug development
Abstract: ChiralityVolume 3, Issue 2 p. 94-98 Commentary and Review Racemic mixtures and single stereoisomers: Industrial concerns and issues in drug development Mitchell N. Cayen, Corresponding Author Mitchell N. Cayen Senior Director Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research, Bloomfield, New Jersey 07003Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research, Bloomfield, New Jersey 07003Search for more papers by this author Mitchell N. Cayen, Corresponding Author Mitchell N. Cayen Senior Director Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research, Bloomfield, New Jersey 07003Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research, Bloomfield, New Jersey 07003Search for more papers by this author First published: 1991 https://doi.org/10.1002/chir.530030203Citations: 67AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Literature Cited 1 Ariens, E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26: 663–668, 1984. 2 Drayer, D.E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin. Pharmacol. Ther. 40: 125–133, 1986. 3 Williams, K., Lee, E. Importance of drug enantiomers in clinical pharmacology. Drugs 30: 333–354, 1985. 4 Lam, Y.W.F. Stereoselectivity: An issue of significant importance in clinical pharmacology. Pharmacotherapy 8: 147–157, 1988. 5 I.W. Wainer, E.E. Drayer, eds. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, 1988. 6 Testa, B., Mayer, J.M. Stereoselective drug metabolism and its significance in drug research. Progr. Drug Res. 32: 249–298, 1988. 7 Jamali, F., Mehvar, R., Pasutto, F.M. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J. Pharmaceut. Sci. 78: 695–715, 1989. 8 Birkett, D.J. Racemates or enantiomers: Regulatory approaches. Clin. Exp. Pharmacol. Physiol. 16: 479–483, 1989. 9 DeCamp, W. The FDA perspective on the development of stereoisomers. Chirality 1: 2–6, 1989. 10 Tucker, G.T., Lennard, M.S. Enantiomer specific pharmacokinetics. Pharmacol. Ther. 45: 309–329, 1990. 11 Mehvar, R., Jamali, F. Pharmacokinetic analysis of the enantiomer inversion of chiral nonsteroidal antiinflammatory drugs. Pharmaceut. Res. 5: 76–79, 1988. Citing Literature Volume3, Issue21991Pages 94-98 ReferencesRelatedInformation
Publication Year: 1991
Publication Date: 1991-01-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 83
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot